Over the past year, as several countries faced the collapse of their economies, each has had to take a close hard look at where its wealth is spent. Needless to say, healthcare and its burgeoning cost factors have now become a huge concern for everyone. While each country is striving to explore solutions within its financial constraints and political viewpoints, we find that most of them are facing very similar challenges.
Disease Prevention and Early Diagnosis are becoming first priorities
While countries engaged in discussions to improve the state of healthcare, universal challenges have come up to the surface. The encouraging factor here is that we might have universal answers to these challenges that might help the whole world rather than specific healthcare systems within each of these nations. One universal problem results from the fact that, for a long time, countries have ignored the impact of effective prevention and early diagnosis in preventing disease and lowering healthcare costs.
No surprises here: it is a challenging exercise to create an accurate long-term cost-benefit model – where any nation would spend billions for the promise of reduced costs 20 to 30 years down the line. In the past, such initiatives would be conveniently ignored amidst urgent “more important” issues. Now, in the wake of the economic collapse, countries have had to invest vast amounts of stimulus funds and they are now evaluating disease prevention and early diagnosis models that promise cost-savings in the future. Developed nations like Canada, United States, United Kingdom and Germany have actually been taking an aggressive look at their healthcare systems in this regard – not only to reduce their future healthcare burden, but also to keep their systems at the forefront of what the world can offer.
The impact of prevention and early diagnosis is magnified for neurological diseases
While it is true that prevention and early diagnosis strategies hold great promise across all our healthcare problems, their benefit is magnified in disease areas where success has been limited. Over the past decade, the threat of neurological diseases have been at the forefront of scientific pursuits, and yet there have been few, if any solutions. Consequently, governments and private companies have been looking at improved prevention and early diagnosis strategies to reduce the long term impact of neurological diseases.
As one of the leading companies at the heart of this changing healthcare landscape, Bioasis is striving towards new technologies to address early diagnosis for neurological diseases. Through biomarker technologies like P97, we may be able to help patients get an accurate and early insight into their risk for developing Alzheimer’s disease. Additionally, by leveraging the biosimilar capabilities of the molecule we might be able to transport treatments across the blood brain barrier and accurately target the treatments to the right tissues in the brain. Our technologies have been maturing at the same time as the world is prioritizing early diagnosis of neurological diseases. This presents a great opportunity for us, as our technologies not only target immediate health challenges but also hold the potential to deliver on long-term health benefits.
